Cuproptosis-related Gene FDX1 As a Prognostic Biomarker for Kidney Renal Clear Cell Carcinoma Correlates with Immune Checkpoints and Immune Cell Infiltration

Overview

Journal Front Genet

Date 2023 Feb 9

PMID 36755576

Authors

Yimin Yao

Haixin Chen

Minjun Lou

Tingting Chen

Affiliations

Soon will be listed here.

Abstract

Kidney renal clear cell carcinoma (KIRC) is not sensitive to radiotherapy and chemotherapy, and only some KIRC patients can benefit from immunotherapy and targeted therapy. Cuproptosis is a new mechanism of cell death, which is closely related to tumor progression, prognosis and immunity. The identification of prognostic markers related to cuproptosis in KIRC may provide targets for treatment and improve the prognosis of KIRC patients. Ten cuproptosis-related genes were analyzed for differential expression in KIRC-TCGA and a prognostic model was constructed. Nomogram diagnostic model was used to screen independent prognostic molecules. The screened molecules were verified in multiple datasets (GSE36895 and GSE53757), and in KIRC tumor tissues by RT-PCR and immunohistochemistry (IHC). Clinical correlation of cuproptosis-related independent prognostic molecules was analyzed. According to the molecular expression, the two groups were divided into high and low expression groups, and the differences of immune checkpoint and tumor infiltrating lymphocytes (TILs) between the two groups were compared by EPIC algorithm. The potential Immune checkpoint blocking (ICB) response of high and low expression groups was predicted by the "TIDE" algorithm. FDX1 and DLAT were protective factors, while CDKN2A was a risk factor. FDX1 was an independent prognostic molecule by Nomogram, and low expressed in tumor tissues compared with adjacent tissues ( < 0.05). FDX1 was positively correlated with CD274, HAVCR2, PDCD1LG2, and negatively correlated with CTLA4, LAG3, and PDCD1. The TIDE score of low-FDX1 group was higher than that of high-FDX1 group. The abundance of CD4 T cells, CD8 T cells and Endothelial cells in FDX1-low group was lower than that in FDX1-high group ( < 0.05). FDX1, as a key cuproptosis-related gene, was also an independent prognostic molecule of KIRC. FDX1 might become an interesting biomarker and potential therapeutic target for KIRC.

Citing Articles

Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.

Ajadee A, Mahmud S, Hossain M, Ahmmed R, Ali M, Reza M PLoS One. 2024; 19(9):e0310843.

PMID: 39348357 PMC: 11441673. DOI: 10.1371/journal.pone.0310843.

Identification of PI3K-AKT Pathway-Related Genes and Construction of Prognostic Prediction Model for ccRCC.

Hu S, Zhang X, Xin H, Guo M, Xiao Y, Chang Z Cancer Rep (Hoboken). 2024; 7(9):e70010.

PMID: 39233640 PMC: 11375326. DOI: 10.1002/cnr2.70010.

Characterization of cuproptosis signature in clear cell renal cell carcinoma by single cell and spatial transcriptome analysis.

Zou X, Liu X, Wang H, Li Z, Zhou C Discov Oncol. 2024; 15(1):300.

PMID: 39044005 PMC: 11266328. DOI: 10.1007/s12672-024-01162-2.

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy.

Liu S, Liu C, Wang Y, Chen J, He Y, Hu K Cancer Med. 2024; 13(10):e7303.

PMID: 38800967 PMC: 11129166. DOI: 10.1002/cam4.7303.

The combination of NDUFS1 with CD4 T cell infiltration predicts favorable prognosis in kidney renal clear cell carcinoma.

Wu D, He L, Xu Z, Tian R, Fan X, Fan J Front Cell Dev Biol. 2023; 11:1168462.

PMID: 37469574 PMC: 10352660. DOI: 10.3389/fcell.2023.1168462.

References

Li S, Bu L, Cai L . Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther. 2022; 7(1):158. PMC: 9106713. DOI: 10.1038/s41392-022-01014-x. View

Clark D, Dhanasekaran S, Petralia F, Pan J, Song X, Hu Y . Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019; 179(4):964-983.e31. PMC: 7331093. DOI: 10.1016/j.cell.2019.10.007. View

Wettschureck N, Strilic B, Offermanns S . Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation. Physiol Rev. 2019; 99(3):1467-1525. DOI: 10.1152/physrev.00037.2018. View

Zhu S, Shanbhag V, Wang Y, Lee J, Petris M . A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance. J Cancer. 2017; 8(11):1952-1958. PMC: 5559955. DOI: 10.7150/jca.19029. View

Xiong Z, Yuan C, Shi J, Xiong W, Huang Y, Xiao W . Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. Theranostics. 2020; 10(25):11444-11461. PMC: 7546001. DOI: 10.7150/thno.48469. View

Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S . BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012; 44(7):751-9. PMC: 3788680. DOI: 10.1038/ng.2323. View

Mayadev J, Enserro D, Lin Y, Da Silva D, Lankes H, Aghajanian C . Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2019; 6(1):92-99. PMC: 6902184. DOI: 10.1001/jamaoncol.2019.3857. View

Liu H . Pan-cancer profiles of the cuproptosis gene set. Am J Cancer Res. 2022; 12(8):4074-4081. PMC: 9442004. View

Bian Z, Fan R, Xie L . A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma. Genes (Basel). 2022; 13(5). PMC: 9141858. DOI: 10.3390/genes13050851. View

10.

Hakimi A, Reznik E, Lee C, Creighton C, Brannon A, Luna A . An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 2016; 29(1):104-116. PMC: 4809063. DOI: 10.1016/j.ccell.2015.12.004. View

11.

Morad G, Carman C, Hagedorn E, Perlin J, Zon L, Mustafaoglu N . Tumor-Derived Extracellular Vesicles Breach the Intact Blood-Brain Barrier Transcytosis. ACS Nano. 2019; 13(12):13853-13865. PMC: 7169949. DOI: 10.1021/acsnano.9b04397. View

12.

Li Y, Fang M, Xu Z, Li X . Tetrathiomolybdate as an old drug in a new use: As a chemotherapeutic sensitizer for non-small cell lung cancer. J Inorg Biochem. 2022; 233:111865. DOI: 10.1016/j.jinorgbio.2022.111865. View

13.

Li H, Wang G, Yu Y, Jian W, Zhang D, Wang Y . α-1,2-Mannosidase MAN1C1 Inhibits Proliferation and Invasion of Clear Cell Renal Cell Carcinoma. J Cancer. 2018; 9(24):4618-4626. PMC: 6299394. DOI: 10.7150/jca.27673. View

14.

Meydan S, Klepacki D, Karthikeyan S, Margus T, Thomas P, Jones J . Programmed Ribosomal Frameshifting Generates a Copper Transporter and a Copper Chaperone from the Same Gene. Mol Cell. 2017; 65(2):207-219. PMC: 5270581. DOI: 10.1016/j.molcel.2016.12.008. View

15.

Lopez J, Ramchandani D, Vahdat L . Copper Depletion as a Therapeutic Strategy in Cancer. Met Ions Life Sci. 2019; 19. DOI: 10.1515/9783110527872-018. View

16.

Yi L, Wu G, Guo L, Zou X, Huang P . Comprehensive Analysis of the PD-L1 and Immune Infiltrates of mA RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma. Mol Ther Nucleic Acids. 2020; 21:299-314. PMC: 7332506. DOI: 10.1016/j.omtn.2020.06.001. View

17.

Zhou P, Qin J, Zhou C, Wan G, Liu Y, Zhang M . Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer. Biomaterials. 2019; 195:86-99. DOI: 10.1016/j.biomaterials.2019.01.007. View

18.

Alsaab H, Sau S, Alzhrani R, Cheriyan V, Polin L, Vaishampayan U . Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials. 2018; 183:280-294. PMC: 6414719. DOI: 10.1016/j.biomaterials.2018.08.053. View

19.

Wang Z, Dong H, Yang L, Yi P, Wang Q, Huang D . The role of FDX1 in granulosa cell of Polycystic ovary syndrome (PCOS). BMC Endocr Disord. 2021; 21(1):119. PMC: 8207664. DOI: 10.1186/s12902-021-00775-w. View

20.

Ren F, Logeman B, Zhang X, Liu Y, Thiele D, Yuan P . X-ray structures of the high-affinity copper transporter Ctr1. Nat Commun. 2019; 10(1):1386. PMC: 6437178. DOI: 10.1038/s41467-019-09376-7. View